Deal analysis part two – the good
A look at big oncology deals since 2016 finds outright success stories hard to come by.
Mesothelin lives on
Work targeting mesothelin, and some other antigens that have hitherto disappointed, continues.
Lack of overall survival doesn't stop Flaura2
Approval on the basis of Flaura2 is part of a double success for Astra's Tagrisso, which has also scored in Laura.
Make or break time for Iovance
Lifileucel heads up the list of upcoming US FDA catalysts.
GSK’s Blenrep Dreamm remains alive
Some light is shed on Dreamm-7, but precisely why this trial was successful remains a mystery.
Takeda taps Protagonist before it’s Verified
Rusfertide’s big readout will now not come until 2025.
Carvykti joins Abecma in adcom limbo
Both BCMA-targeting Car-T therapies will face US advisory committee scrutiny after all.
